

29 June 2023

ASX Code: MXC

LSE Code: MXC

Results of Shareholder's General Meeting

A
S
X

R
E
L
E
A
S
E

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') would like to announce the results from the Company's General Meeting of Shareholders held today, Thursday, 29 June 2023, in accordance with ASX Listing Rule 3.13.2.

The Company confirms that all motions put to the meeting were voted by poll, with all resolutions carried.

Details of the proxy voting and voting outcomes for all motions put to the meeting are set out in the attached report.

—Ends—

Authorised for release by the Company Secretary, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer
CEO & Managing Director
+61 8 6382 3390
info@mgcpharma.com.au

UK Brokers

Peterhouse Capital

Charles Goodfellow / Lucy Williams / Duncan Vasey
+44 207 469 0930
cg@peterhousecap.com / lw@peterhousecap.com

UK IR/PR Advisers

IFC Advisory

Graham Herring / Tim Metcalfe / Zach Cohen
mgcpharma@investor-focus.co.uk

MGC Pharmaceuticals Ltd

Arron Canicais / Rowan Harland
Joint Company Secretaries
+61 8 6382 3390
info@mgcpharma.co.uk

UK Brokers

Oberon Capital

Aimee McCusker / Adam Pollock
+44 203 179 5300
aimeemccusker@oberoninvestments.com
adampollock@oberoninvestments.com

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil, and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Ratification of prior issue of Convertible Notes	Ordinary	543,593,510 85.91%	52,165,169 8.24%	37,026,148 5.85%	56,764,036	580,723,818 91.76%	52,165,169 8.24%	56,764,036	Carried
2A Ratification of prior issue of Options	Ordinary	368,387,517 80.56%	51,696,443 11.31%	37,190,024 8.13%	56,722,261	405,681,701 88.70%	51,696,443 11.30%	56,722,261	Carried
2B Ratification of prior issue of Options	Ordinary	348,372,588 71.06%	104,852,239 21.39%	37,016,684 7.55%	23,754,734	385,493,432 78.62%	104,852,239 21.38%	23,754,734	Carried
3 Ratification of prior issue of Shares	Ordinary	518,193,406 78.49%	105,084,039 15.91%	37,016,684 5.60%	23,754,734	555,314,250 84.09%	105,084,039 15.91%	23,754,734	Carried
4 Approval for Share Placement	Ordinary	644,519,843 81.72%	106,724,952 13.53%	37,466,684 4.75%	3,337,384	682,090,687 86.47%	106,724,952 13.53%	3,337,384	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.